June 2013
Volume 54, Issue 15
Free
ARVO Annual Meeting Abstract  |   June 2013
Navigated Laser Photocoagulation to Reduce Frequency of Bevacizumab Injections (ivB) for Diabetic Macular Edema: 1-Year Results
Author Affiliations & Notes
  • Giulio Barteselli
    Ophthal-Jacobs Retina Ctr, Univ of California San Diego, La Jolla, CA
  • Su-Na Lee
    Ophthal-Jacobs Retina Ctr, Univ of California San Diego, La Jolla, CA
  • Igor Kozak
    Ophthal-Jacobs Retina Ctr, Univ of California San Diego, La Jolla, CA
  • Jay Chhablani
    Ophthal-Jacobs Retina Ctr, Univ of California San Diego, La Jolla, CA
  • Sharif El-Emam
    Ophthal-Jacobs Retina Ctr, Univ of California San Diego, La Jolla, CA
  • William Freeman
    Ophthal-Jacobs Retina Ctr, Univ of California San Diego, La Jolla, CA
  • Footnotes
    Commercial Relationships Giulio Barteselli, None; Su-Na Lee, None; Igor Kozak, None; Jay Chhablani, None; Sharif El-Emam, None; William Freeman, OD-OS, Inc. (C)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 2379. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Giulio Barteselli, Su-Na Lee, Igor Kozak, Jay Chhablani, Sharif El-Emam, William Freeman; Navigated Laser Photocoagulation to Reduce Frequency of Bevacizumab Injections (ivB) for Diabetic Macular Edema: 1-Year Results. Invest. Ophthalmol. Vis. Sci. 2013;54(15):2379.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: To evaluate frequency of ivB in DME patients in a combined treatment protocol with grid/focal navigated laser photocoagulation, and to characterize microaneurysm closure after treatment.

Methods: 57 eyes with DME of 45 consecutive patients were enrolled. At baseline, patients underwent BCVA measurement, fluorescein angiography and SD-OCT. Eyes with CRT≥ 400 µm (group 1) received 3 monthly ivB followed by grid/focal navigated laser treatment with Navilas photocoagulator (OD-OS, Germany). Eyes with CRT< 400 µm (group 2) received navigated laser treatment only. During 12-month follow-up, in cases with an increase in CRT ≥20% from baseline with a loss of ≥5 letters, group 1 was allowed to receive further ivB, while group 2 received laser treatment. In cases exceeding 400 µm in CRT, eyes were allowed to shift from group 2 to group 1. Leaking microaneurysms were analyzed and followed for 12 months to assess their closure after laser treatment.

Results: 27 eyes were enrolled in group 1 and 30 eyes in group 2. In group 1, BCVA improved of 13.3 letters at 12 months from baseline (p=0.01) with an average of 3.7 ivB. In group 2, a non-significant improvement of 2.1 letters was achieved. Overall, BCVA improved of 7.6 letters (p<0.01), with an average of 1.9 ivB. In 12 months, 33% of the eyes of group 1 required additional ivB. In group 2, 4 eyes (13%) required additional laser treatment and 4 eyes shifted to group 1 and received 3 ivB. In group 1, CRT improved from 436 to 342 µm (p<0.001), while in group 2 CRT was stable after 12 months. Overall, CRT improved from 347 to 319 µm (p<0.001). Closure rate of 123 treated microaneurysms was 69.9% at 3 months, and increased to 82.9% at 12 months (p<0.001). Half of closed microaneurysms left hyper-reflective spots on SD-OCT, while half of them disappeared at 3 months. Microaneurysm closure was positively associated with smaller diameter (p<0.001), and heterogeneous lumen reflectivity (p<0.03).

Conclusions: Combined therapy with ivB and navigated laser photocoagulation limited the frequency of ivB required in eyes with DME. Visual results and retreatment rates after 12 months compared favorably with results obtained in randomized clinical trial. Treated microaneurysms resulted in hyper-reflective spots on SD-OCT or disappeared after 3 months. Closure rate was higher in cases of small microaneurysms and heterogeneous lumen reflectivity.

Keywords: 505 edema • 498 diabetes • 578 laser  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×